

Board of Governors of the Federal Reserve System, February 22, 2021.

Michele Taylor Fennell,

Deputy Associate Secretary of the Board.

[FR Doc. 2021-03952 Filed 2-25-21; 8:45 am]

BILLING CODE P

FEDERAL RESERVE SYSTEM

Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company

The notificants listed below have applied under the Change in Bank Control Act (Act) (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the applications are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board's Freedom of Information Office at <https://www.federalreserve.gov/foia/request.htm>. Interested persons may express their views in writing on the standards enumerated in paragraph 7 of the Act.

Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue, NW, Washington DC 20551-0001, not later than March 15, 2021.

A. Federal Reserve Bank of San Francisco (Sebastian Astrada, Director, Applications) 101 Market Street, San Francisco, California 94105-1579:

1. *Hamad Abdulmohsen Almarzouq, Abeer Abdullah Alsemait, Abdulaziz Yacoub Alnafisi, Ahmad Abdulaziz Alnafisi, Aljuohara Abdulaziz Alnafisi, Dalal Abdulaziz Alnafisi, Farah Abdulaziz Alnafisi, all of Yarmook, Kuwait;*

Ghaida Husain Alhusain, Duaij Khalifah Khalaf Alenezi, Samir Yaqoub Alnafisi, Suliman Khalifah Khalaf Alenezi, all of Kuwait City, Kuwait;

Abrar Khaled Alsabah, Jaber Khaled Alsabah, Ohoud Salem Alsabah, Salem Khaled Alsabah, Shaikhah Khaled Alsabah, all of Qortuba, Al Asimah, Kuwait;

Khalid Abdullah Alsumait, Shatha Abdullah Alsamait, both of Dahiya Abdullah Salem, Kuwait;

Areej Abdullah Alsamait, Shuwaikh, Kuwait; and

Issam Abdulmohsen Almarzooq, Abdullah Alsalem, Kuwait; as a group acting in concert to acquire voting shares of Greater Pacific Bancshares, and thereby indirectly acquire voting shares of Bank of Whittier, National Association, both of Whittier, California.

Board of Governors of the Federal Reserve System, February 22, 2021.

Michele Taylor Fennell,

Deputy Associate Secretary of the Board.

[FR Doc. 2021-03953 Filed 2-25-21; 8:45 am]

BILLING CODE P

FEDERAL RESERVE SYSTEM

Notification of Amendment to the Rules of Organization; Federal Open Market Committee

AGENCY: Federal Open Market Committee, Federal Reserve System.

SUMMARY: The Federal Open Market Committee amended its Rules of Organization to replace the terms "Chairman" and "Vice Chairman" with "Chair" and "Vice Chair," respectively.

DATES: The amendments to the Rules of Organization became effective on February 17, 2021.

FOR FURTHER INFORMATION CONTACT: Matthew Luecke, Deputy Secretary of the Federal Open Market Committee, (202) 452-2576, 20th and C Streets NW, Washington, DC 20551; or Alye S. Foster, Deputy Associate General Counsel (202-452-5289), Legal Division, Board of Governors of the Federal Reserve System.

SUPPLEMENTARY INFORMATION: The Federal Open Market Committee (Committee) has replaced the references in its Rules of Organization to "Chairman" and "Vice Chairman," with "Chair" and "Vice Chair," respectively. Although the terms "Chairman" and "Vice Chairman" are referenced in the Federal Reserve Act, traditionally these terms have been used to refer to persons regardless of gender. As the terms are not intended to be and, in practice, are not gender-specific, the Committee is replacing the terms "Chairman" and "Vice Chairman" in the Committee's Rules of Organization with their gender-neutral equivalents of "Chair" and "Vice Chair," respectively. This change also aligns the Committee's Rules of Organization with its practice.

The Committee has incorporated the amendments into the Committee's Rules of Organization, which are uncoded

regulations for use by the Committee and are issued pursuant to 5 U.S.C. 552. Because the amendments relate solely to the internal organization, procedure, or practice of the Committee, the public notice, public comment, and delayed effective date provisions of the Administrative Procedure Act do not apply. See 5 U.S.C. 553(b) and (d).

For the reasons discussed above the Committee has amended its Rules of Organization as follows:

All references to "Chairman" and "Vice Chairman" are revised to read "Chair" and "Vice Chair," respectively, wherever they appear.

By order of the Federal Open Market Committee.

Matthew M. Luecke,

Deputy Secretary, Federal Open Market Committee.

[FR Doc. 2021-04040 Filed 2-25-21; 8:45 am]

BILLING CODE 6210-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment (CHACHSPT)

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice of meeting.

SUMMARY: In accordance with the Federal Advisory Committee Act, the CDC and the Health Resources and Services Administration (HRSA), announces the following meeting for the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment (CHACHSPT). This meeting is open to the public, limited only by audio and web conference lines (1,000 audio and web conference lines are available). The public is welcome to listen to the meeting by accessing the telephone number 1-669-254-5252, and the passcode is 47035054 (1,000 lines are available). The web conference access is <https://cdc.zoomgov.com/j/1617148601?pwd=eVBTM0dweHFxQUxWUzU2OEttY1R1QT09>, webinar ID: 161 714 8601 and passcode: v08w0@e5.

DATES: The meeting will be held on April 20, 2021, from 1:00 p.m. to 5:00 p.m., EDT and April 21, 2021, from 1:00 p.m. to 5:00 p.m., EDT.

ADDRESSES: The teleconference access is 1-669-254-5252, and the passcode is 47035054. The web conference access is <https://cdc.zoomgov.com/j/>

1617148601?pwd=eVBTM0dweHFx
QUxWUzU2OEtY1R1QT09, webinar ID:
161 714 8601, and passcode: v08w0@e5.

FOR FURTHER INFORMATION CONTACT:

Staci Morris, Committee Management Specialist, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC, 1600 Clifton Road NE, Mailstop US8–6, Atlanta, Georgia 30329–4027, Telephone: (404) 718–7479; smorris4@cdc.gov.

SUPPLEMENTARY INFORMATION: Time will be available for public comment. The public is welcome to submit written comments in advance of the meeting. Comments should be submitted in writing by email to the contact person listed below by Monday, April 19, 2021. Persons who desire to make an oral statement, may request it at the time of the public comment period on April 20, 2021 at 4:25 p.m., EDT.

Purpose: This committee is charged with advising the Director, CDC, and the Administrator, HRSA, regarding activities related to prevention and control of HIV, Viral Hepatitis and other STDs, the support of health care services to persons living with HIV, and education of health professionals and the public about HIV, Viral Hepatitis and other STDs.

Matters To Be Considered: The agenda will include discussions on (1) STI Screening and Diagnostics; (2) Innovation and COVID–19; and (3) Youth and Mental Health. Agenda items are subject to change as priorities dictate.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2021–03962 Filed 2–25–21; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment (CHACHSPT)

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice of meeting.

SUMMARY: In accordance with the Federal Advisory Committee Act, the CDC and the Health Resources and Services Administration (HRSA) announce the following meeting for the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment (CHACHSPT). This business meeting is open to the public, limited only by audio and web conference lines (1000 audio and web conference lines are available). The public is welcome to listen to the meeting by accessing the telephone number 1–669–254–5252, and the passcode is 55572151 (1000 lines are available). The web conference access is <https://cdc.zoomgov.com/j/1606419940?pwd=V2krVkVXbGtvVFdLbXV3N25PbTV4UT09>, webinar ID: 160 641 9940 and passcode: ZeTt@2VL.

DATES: The business meeting will be held on April 12, 2021, from 3:00 p.m. to 5:00 p.m., EDT.

ADDRESSES: The teleconference access is 1–669–254–5252, and the passcode is 55572151. The web conference access is <https://cdc.zoomgov.com/j/1606419940?pwd=V2krVkVXbGtvVFdLbXV3N25PbTV4UT09>, webinar ID: 160 641 9940 and passcode: ZeTt@2VL.

FOR FURTHER INFORMATION CONTACT:

Staci Morris, Committee Management Specialist, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC, 1600 Clifton Road NE, Mailstop US8–6, Atlanta, Georgia 30329–4027, Telephone (404) 718–7479; smorris4@cdc.gov.

SUPPLEMENTARY INFORMATION:

Purpose: This committee is charged with advising the Director, CDC and the Administrator, HRSA, regarding activities related to prevention and control of HIV, Viral Hepatitis and other STDs, the support of health care services to persons living with HIV/AIDS, and education of health professionals and the public about HIV, Viral Hepatitis and other STDs.

Matters To Be Considered: The agenda will include discussions on (1) HIV Testing Guidelines; and (2) FDA

reclassification, home-based HIV self-tests and point-of-care testing for HCV. Agenda items are subject to change as priorities dictate.

The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2021–03961 Filed 2–25–21; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Clinical Laboratory Improvement Advisory Committee (CLIAC)

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

ACTION: Notice of meeting.

SUMMARY: In accordance with the Federal Advisory Committee Act, the CDC announces the following meeting for the Clinical Laboratory Improvement Advisory Committee (CLIAC). This meeting is open to the public, limited only by the webcast lines available. Check the CLIAC website on the day of the meeting for the web conference link www.cdc.gov/cliac.

DATES: The meeting will be held on April 14, 2021, from 11:00 a.m. to 6:00 p.m., EDT and April 15, 2021, from 11:00 a.m. to 6:00 p.m., EDT.

ADDRESSES: This is a virtual meeting. Meeting times are tentative and subject to change. The confirmed meeting times, agenda items, and meeting materials including instructions for accessing the live meeting broadcast will be available on the CLIAC website at www.cdc.gov/cliac.

FOR FURTHER INFORMATION CONTACT:

Nancy Anderson, MMSc, MT (ASCP), Senior Advisor for Clinical Laboratories, Division of Laboratory Systems, Center for Surveillance, Epidemiology and Laboratory Services, Office of Public Health Scientific Services, Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop V24–3,